Revisiting intraperitoneal chemotherapy for advanced high‐grade serous ovarian cancer
Abstract
Objective
To compare overall survival (OS) in patients with high‐grade serous ovarian cancer (HGSOC) treated with intraperitoneal (IP) chemotherapy versus intravenous (IV) chemotherapy.
Methods
A retrospective study of Stage III HGSOC with optimal primary cytoreduction during 2007–2019, followed by adjuvant IP or IV chemotherapy.
Results
Overall, 54 patients were included, 23 (43%) treated by IP and 31 (57%) by IV chemotherapy. Median progression‐free survival (PFS) in the IP group was 39 months (95% confidence interval [CI] 34–44 months) versus 23 months (95% CI 18–28 months) in the IV group ( P = 0.294). The IP chemotherapy had superior OS compared with IV chemotherapy, with median OS not reached, versus 76 months (95% CI 37–115 months) for the IV group ( P = 0.075, hazard ratio 0.45, 95% CI 0.18–1.10). At 72 months, OS was 82% for the IP group versus 53% in the IV group. In a sensitivity analysis for Stage IIIc patients only ( n = 39), the median OS was 130 months (95% CI 86–174 months) in the IP group, compared with 56 months (95% CI 35–76 months) for the IV group ( P = 0.152). Toxicity profiles were similar in both groups, with no Grade ≥3 toxicity.
Conclusion
Stage III HGSOC patients treated with IP chemotherapy had significantly longer OS.